Meeting
2022 ASCO Annual Meeting
Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation.
Authors
Lars M. Wagner
Duke University Medical Center, Durham, NC
Lars M. Wagner , Leo Mascarenhas , Michael Isakoff , Bhuvana Setty , Joanne P. Lagmay , Emi Caywood , Eric Stuart Sandler , Christine A. Pratilas , Scott C. Borinstein , Matteo M. Trucco , Brooke Fridley , Damon R. Reed , Javier E. Oesterheld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02945800
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10042)
DOI
10.1200/JCO.2022.40.16_suppl.10042
Abstract #
10042
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2020 ASCO Virtual Scientific Program
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
First Author: Jaime Feliu Batlle
Poster
2018 ASCO Annual Meeting
A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.
First Author: Manisha Palta
Poster
2017 ASCO Annual Meeting
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Philippa Corrie